E
Esther Drees
Researcher at VU University Medical Center
Publications - 2
Citations - 165
Esther Drees is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 2, co-authored 2 publications receiving 138 citations.
Papers
More filters
Journal ArticleDOI
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
R. Jonas A. Nilsson,Niki Karachaliou,Jordi Berenguer,Ana Giménez-Capitán,Pepijn Schellen,Cristina Teixidó,Jihane Tannous,Justine L. Kuiper,Esther Drees,Magda Grabowska,Marte van Keulen,Daniëlle A.M. Heideman,Erik Thunnissen,Anne-Marie C. Dingemans,Santiago Viteri,Bakhos A. Tannous,Ana Drozdowskyj,Rafael Rosell,Egbert F. Smit,Thomas Wurdinger +19 more
TL;DR: Platelets are a valuable source for the non-invasive detection of EML4-ALK rearrangements and may prove useful for predicting and monitoring outcome to crizotinib, thereby improving clinical decisions based on radiographic imaging alone.
Journal ArticleDOI
EML4-ALK rearrangement in blood platelets and outcome to crizotinib in non-small-cell lung cancer patients.
Niki Karachaliou,R. Jonas A. Nilsson,Jordi Berenguer,Ana Gimenez Capitan,Pepijn Schellen,Cristina Teixidó,Justine L. Kuiper,Esther Drees,Magda Grabowska,Marte van Keulen,Jihane Tannous,Daniëlle A.M. Heideman,Erik Thunnissen,Anne-Marie C. Dingemans,Santiago Viteri Ramirez,Bakhos A. Tannous,Ana Drozdowskyj,Egbert F. Smit,Thomas Wurdinger,Rafael Rosell +19 more
TL;DR: In a subset of 29 p with EML4-ALK-rearranged tumors treated with crizotinib, EML 4-ALK rearrangements in platelets were correlated with progression-free survival (PFS) and overall survival (OS).